Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases

Sumeet K. Asrani, Marwan S. Ghabril, Alexander Kuo, Raphael B. Merriman, Timothy Morgan, Neehar D. Parikh, Nadia Ovchinsky, Fasiha Kanwal, Michael L. Volk, Chanda Ho, Marina Serper, Shivang Mehta, Vatche Agopian, Roniel Cabrera, Victoria Chernyak, Hashem B. El‐Serag, Julie Heimbach, George N. Ioannou, David Kaplan, Jorge Marrero, Neil Mehta, Amit Singal, Riad Salem, Tamar Taddei, Anne M. Walling, Elliot B. Tapper – 14 November 2021 – The burden of HCC is substantial.

Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests

Amy L. Johnson, Kelly L. Hayward, Preya Patel, Leigh U. Horsfall, Alvin Ee Zhiun Cheah, Katharine M. Irvine, Anthony W. Russell, Katherine A. Stuart, Sue Williams, Gunter Hartel, Patricia C. Valery, Elizabeth E. Powell – 14 November 2021 – It remains unclear whether screening for advanced fibrosis in the community can identify the subgroup of people with nonalcoholic fatty liver disease (NAFLD) at higher risk for development of liver‐related complications.

Immunogenicity and Adverse Effects of the 2‐Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients

Yana Davidov, Keren Tsaraf, Oranit Cohen‐Ezra, Mariya Likhter, Gil Ben Yakov, Itzchak Levy, Einav G. Levin, Yaniv Lustig, Orna Mor, Galia Rahav, Ziv Ben Ari – 11 November 2021 – The BNT162b2 messenger RNA (mRNA) vaccine against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been shown to be safe and effective in immunocompetent patients. The safety and efficacy of this vaccine in liver transplantation (LT) recipients is still under evaluation. The objective of this study was to assess the safety and efficacy of the BNT162b2 vaccine among transplant recipients.

Subscribe to